```
<!--StartFragment-->RESULT 2
ABA00656
TD
    ABA00656 standard; cDNA; 3400 BP.
XX
AC
    ABA00656:
XX
DT
    19-FEB-2003 (first entry)
XX
DF.
    Human ENZM-4 cDNA, incyte ID No: 3535146CB1.
XX
KW
    Gene; ENZM; cardiovascular disorder; arteriovenous fistula; prostate;
     atherosclerosis; hypertension; Raynaud's disease; aneurysm; cervix;
KW
    varicose vein; thrombophlebitis; congestive heart failure; brain; breast;
KW
     angina pectoris; ischaemic; heart disease; autoimmune; inflammation;
KW
KW
     acquired immunodeficiency syndrome; anaemia; asthma; Crohn's disease;
KW
     neurological disorder; epilepsy; Huntington's disease; dementia; stroke;
KW
    Alzheimer's disease; Creutzfeldt-Jakob disease; multiple sclerosis;
KW
    cerebral palsy; Parkinson's disease; anxiety; schizophrenia; amnesia;
KW
    metabolic disorder; Addison's disease; goitre; infection; sarcoma;
KW
    pneumonia; hepatitis; influenza; immune deficiency; thymic dysplasia;
     severe combined immunodeficiency disease; reproduction; infertility;
KW
     endometriosis: prostatis: Pevronie's disease: impotence: eve disorder:
KW
     glaucoma; ocular hypertension; cell proliferation; psoriasis; myeloma;
KW
    polycythemia vera; cancer; adenocarcinoma; leukemia; lymphoma; melanoma;
KW
KW
    MDMCSF; ss.
XX
OS
    Homo sapiens.
XX
                    Location/Oualifiers
FΗ
    Kev
    CDS
                     66. .3002
FT
FT
                     /*tag= a
FΤ
                     /product= "ENZM-4 protein"
XX
    W0200283873-A2.
PN
XX
PD
    24-OCT-2002.
XX
PF
    10-APR-2002; 2002WO-US015253.
XX
    13-APR-2001; 2001US-0283793P.
PR
PR
    16-MAY-2001; 2001US-0291544P.
    25-MAY-2001; 2001US-0293572P.
PR
PR
    27-JUL-2001: 2001US-0308182P.
PR
    09-AUG-2001; 2001US-0311447P.
PR
    29-AUG-2001: 2001US-0315874P.
PR
    14-SEP-2001; 2001US-0322181P.
XX
PA
     (INCY-) INCYTE GENOMICS INC.
XX
```

```
PI Tang YT, Yue H, Sanjanwala MM, Ramkumar J, Yao MG, Swarnakar A;
PI Ding L, Elliott VS, Griffin JA, Li JX, Lal PG, Lu DAM, Lu Y;
PI Gorvad AE, Forsythe IJ, Duggan BM, Thangavelu K, Emerling BM;
PI Hafalia AJA, Baughn MR, Becha S, Sprague WW;
```

DR WPI; 2003-075542/07.
DR P-PSDB: AAG79674.

XX PT PT

New human enzymes and polynucleotides, useful for diagnosing, treating or preventing cardiovascular disorders (e.g. aneurysms), neurological disorders (e.g. Parkinson's disease), cancers or autoimmune/inflammatory disorders.

PT XX PS XX

SO

PТ

Claim 5; Page 194-95; 203pp; English.

CC The sequences given in ABA00653-64 encode human enzymes designated ENZM. CC The polypeptide or polynucleotide of the invention are useful for CC treating a disease or condition associated with decreased expression of CC functional ENZM. Antagonists of ENZM are useful for treating a disease or condition associated with overexpression of functional ENZM. Anti-ENZM CC CC antibodies are particularly useful for diagnosing, treating or preventing CC cardiovascular disorders (e.g. arteriovenous fistula, atherosclerosis, CC hypertension, Raynaud's disease, aneurysms, varicose veins, CC thrombophlebitis, congestive heart failure, angina pectoris, ischaemic CC heart disease or rheumatic heart disease), autoimmune/inflammatory CC disorders (e.g. acquired immunodeficiency syndrome, anaemia, asthma, or Crohn's disease), neurological disorders (e.g. epilepsy, Huntington's CC

CC disorders (e.g. acquired immunodeficiency syndrome, anaemia, asthma, or CC Crohn's disease), neurological disorders (e.g. epilepsy, Huntington's CC disease, dementia, stroke, Alzheimer's disease, Creutzfeldt-Jakob CC disease, multiple sclerosis, cerebral palsy, Parkinson's disease, anxiety, schizophrenia or amnesia), metabolic disorders (e.g. Addison's CC disease or goitre), infectious disorders (e.g. viral infection, CC pneumonia, hepatitis or influenza), immune deficiencies (e.g. thymic CC dysplasia or severe combined immunodeficiency disease), reproductive

disorders (e.g. infertility, endometriosis, prostatis, Peyronie's disease or impotence), eye disorders (e.g. glaucoma or ocular hypertension), or cell proliferative disorders (e.g. psoriasis, polycythemia vera, or cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, cc sarcoma, or cancers of the brain, breast, cervix or prostate). The protein encoded by this sequence is homologous to human MDMCSF

Sequence 3400 BP; 894 A; 809 C; 908 G; 789 T; 0 U; 0 Other;

Query Match 100.0%; Score 2934; DB 8; Length 3400; Best Local Similarity 100.0%; Pred. No. 0; Matches 2934; Conservative 0; Mismatches 0; Indels 0; Gaps

0;

Qy	61	CCTCCGGCCGCCTCCGTGTGCCCTTCGCGCTAGCAGCGGCGGCGGGGGGGG	120
Db	126	CCTCCGCGCCCCCCGTGTGCCCCTGTCGCGCTAGCAGCGGCGGCGGCGGAGGCGGCGGC	185
Qy	121	GGTGGCCGGGAGGGCCTGCTTGGACAGCGGCGGCCGCAGGATGGCCAGGCCCGGAGCAGC	180
Db	186	$\tt GGTGGCCGGGAGGGCCTGCTTGGACAGCGGGGGCGGGAGGATGGCCAGGCCCGGAGCAGC$	245
Qy	181	TGCAGCCCCGGCGGCCGAACGCCCGCGGCGCGGGACTCCATCGTCAGAGAAGTCATTCAG	240
Db	246	$\tt TGCAGCCCCGGCGGCGCGAACGCCCGCGGGGGGACTCCATCGTCAGAGAAGTCATTCAG$	305
Qу	241	AATTCAAAAGAAGTTCTAAGTTTATTGCAAGAAAAAAACCCTGCCTTCAAGCCGGTTCTT	300
Db	306	${\tt AATTCAAAAGAAGTTCTAAGTTTATTGCAAGAAAAAAACCCTGCCTTCAAGCCGGTTCTT}$	365
Qy	301	GCAATTATCCAGGCAGGTGACGACAACTTGATGCAGGAAATCAACCAGAATTTGGCTGAG	360
Db	366	${\tt GCAATTATCCAGGCAGGTGACGACAACTTGATGCAGGAAATCAACCAGAATTTGGCTGAG}$	425
Qy	361	GAGGCTGGTCTGAACATCACTCACATTTGCCTCCCTCCAGATAGCAGTGAAGCCGAGATT	420
Db	426		485
Qy	421	ATAGATGAAATCTTAAAGATCAATGAAGATACCAGAGTACATGGCCTTGCCCTTCAGATC	480
Db	486	${\tt ATAGATGAAATCTTAAAGATCAATGAAGATACCAGAGTACATGGCCTTGCCCTTCAGATC}$	545
Qу	481	TCTGAGAACTTGTTTAGCAACAAAGTCCTCAATGCCTTGAAACCAGAAAAAAGATGTGGAT	540
Db	546	${\tt TCTGAGAACTTGTTTAGCAACAAAGTCCTCAATGCCTTGAAACCAGAAAAAGATGTGGAT}$	605
Qy	541	GGAGTAACAGACATAAACCTGGGGAAGCTGGTGCGAGGGGATGCCCATGAATGTTTTGTT	600
Db	606	GGAGTAACAGACATAAACCTGGGGAAGCTGGTGCGAGGGGATGCCCATGAATGTTTTGTT	665
Qy	601	TCACCTGTTGCCAAAGCTGTAATTGAACTTCTTGAAAAATCAGGTGTCAACCTAGATGGA	660
Db	666	${\tt TCACCTGTTGCCAAAGCTGTAATTGAACTTCTTGAAAAATCAGGTGTCAACCTAGATGGA}$	725
Qу	661	AAGAAGATTTTGGTAGTGGGGGCCCATGGGTCTTTGGAAGCTGCTCTACAATGCCTGTTC	720
Db	726		785
Qy	721	CAGAGAAAAGGGTCCATGACAATGAGCATCCAGTGGAAAACACGCCAGCTTCAAAGCAAG	780
Db	786	${\tt CAGAGAAAAGGGTCCATGACAATGAGCATCCAGTGGAAAACACGCCAGCTTCAAAGCAAG}$	845

Db

Qv.

Db	906		965
Qу	901	$\tt GGGTGTGGCTCTCCAAGAATACATTTTGGTGGACTCATTGAGGAAGATGATGTGATTCTC$	960
Db	966	GGGTGTGGCTCTCCAAGAATACATTTTGGTGGACTCATTGAGGAAGATGATGTGATTCTC	1025
Qу	961	CTTGCTGCAGCTCTGCGAATTCAGAACATGGTCAGTAGTGGAAGGAGATGGCTTCGTGAA	1020
Db	1026	CTTGCTGCAGCTCTGCGAATTCAGAACATGGTCAGTAGTGGAAGGAGATGGCTTCGTGAA	1085
Qу	1021	CAGCAGCACAGGCGGTGGAGACTTCACTGCTTGAAACTTCAGCCTCTCTCCCCTGTGCCA	1080
Db	1086	${\tt CAGCAGCACAGGCGGTGGAGACTTCACTGCTTGAAACTTCAGCCTCTCTCCCCTGTGCCA}$	1145
Qу	1081	AGTGACATTGAGATTTCAAGAGGACAAACTCCAAAAGCTGTGGATGTCCTTGCCAAGGAG	1140
Db	1146	${\tt AGTGACATTGAGATTTCAAGAGGACAAACTCCAAAAGCTGTGGATGTCCTTGCCAAGGAG}$	1205
Qу	1141	ATTGGATTGCTTGCAGATGAAATTGAAATCTATGGCAAAAGCCAAAGTACGTTTG	1200
Db	1206	ATTGGATTGCTTGCAGATGAAATTGAAATCTATGGCAAAAGCCAAAGTACGTTTG	1265
Qу	1201	TCCGTGCTAGAAAGGTTAAAGGATCAAGCAGATGGAAAATACGTCTTAGTTGCTGGGATC	1260
Db	1266	${\tt TCCGTGCTAGAAAGGTTAAAGGATCAAGCAGATGGAAAATACGTCTTAGTTGCTGGGATC}$	1325
QУ	1261	ACACCCACCCCTCTTGGAGAAGGGAAGAGCACAGTCACCATCGGGCTTGTGCAGGCTCTG	1320
Db	1326	${\tt ACACCCACCCCTCTTGGAGAAGGGAAGAGCACAGTCACCATCGGGCTTGTGCAGGCTCTG}$	1385
Qу	1321	ACCGCACACCTGAATGTCAACTCCTTTGCCTGCTTGAGGCAGCCCTTCCCAAGGACCGACG	1380
Db	1386	${\tt ACCGCACACCTGAATGTCAACTCCTTTGCCTGCTTGAGGCAGCCTTCCCAAGGACCGACG}$	1445
Qу	1381	TTTGGAGTGAAAGGAGCCCCGGGTGGTGGTATATCCCCAGGTCATCCCCATGGAGGAG	1440
Db	1446	${\tt TTTGGAGTGAAAGGAGGCCGCGGGTGGTGGATATGCCCAGGTCATCCCCATGGAGGAG}$	1505
Qу	1441	TTCAACCTTCACTTGACTGGAGACATCCACGCCATCACCGCTGCCAATAACTTGCTGGCT	1500
Db	1506	${\tt TTCAACCTTCACTTGACTGGAGACATCCACGCCATCACCGCTGCCAATAACTTGCTGGCT}$	1565
Qу	1501	${\tt GCCGCCATCGACACGAGGATTCTTCATGAAAACACGCAAACAGATAAGGCTCTGTATAAT}$	1560
http://es/ScoreAc	cessWeb/C	ietliem.action?Appld=105739604_152742_us-10-573-969-1.rng<emType=4&startByte=0 (4 of 6)4/24/2008 1:13:55 PM	

846 CTTCACGAGGCTGACATTGTGGTCCTAGGCTCACCTAAGCCAGAAGAGATTCCCCTTACT 905

841 TGGATACAACCAGGAACTACTGTTCTCAACTGCTCCCATGACTTCCTGTCAGGGAAGGTT 900

Db

Qу

Db

Qу	1621	AAAAAACTGGGAATAAATAAGACTGATCCGAGCACACTGACAGAAGAGGAAGTGAGTAAA	1680
Db	1686	AAAAAACTGGGAATAAATAAGACTGATCCGAGCACACTGACAGAAGAGGAAGTGAGTAAA	1745
Qy	1681	TTTGCCCGTCTCGACATCGACCCATCTACCATCACGTGGCAGAGAGTATTGGATACAAAT	1740
Db	1746	${\tt TTTGCCCGTCTCGACATCGACCCATCTACCATCACGTGGCAGAGAGTATTGGATACAAAT}$	1805
QУ		GACCGATTTCTACGAAAAATAACCATCGGGCAGGGAAACACAGAGAAGGGCCATTACCGG	
Db		GACCGATTTCTACGAAAAATAACCATCGGGCAGGGAAACACAGAGAAGGGCCATTACCGG	
Qy Db		CAGGCGCAGTTTGACATCGCAGTGGCCAGCGAGATCATGGCGGTGCTGGCCCTGACGGAC	
Qy	1861	AGCCTCGCAGACATGAAGGCACGGCTGGGAAAGATGGTGGTGGCCAGTGACAAAAGCGGG	1920
Db	1926	AGCCTCGCAGACATGAAGGCACGGCTGGGAAGGATGGTGGTCGCCAGTGACAAAAGCCGG	1985
Qy	1921	CAGCCTGTGACAGCAGATGATTTGGGGGTGACAGGTGCTTTGACAGTTTTGATGAAAGAT	1980
Db		${\tt CAGCCTGTGACAGCAGATGATTTGGGGGTGACAGGTGCTTTGACAGTTTTGATGAAAGAT}$	
QУ		GCAATAAAACCAAACCTGATGCAGACCCTGGAAGGGACACCTGTGTTCGTGCATGCGGGC	
Db		GCAATAAAACCAAACCTGATGCAGACCCTGGAAGGGACACCTGTTTCGTGCATGCGGGC	
Qy Db		CCTTTTGCTAACATTGCTCACGGCAACTCTTCAGTGTTGGCTGATAAAATTGCCCTGAAA	
Qv		CTGGTTGGTGAAGAAGGATTTGTAGTGACCGAAGCTGGCTTTGGTGCTGACATCGGAATG	
Db		CTGGTTGGTGAAGAAGGATTTGTAGTGACCGAAGCTGGCTTTGGTGCTGACATCGGAATG	
Qу	2161	GAGAAATTCTTCAACATCAAGTGCCGAGCTTCCGGCTTGGTGCCCAACGTGGTTGTGTTA	2220
Db	2226	GAGAAATTCTTCAACATCAAGTGCCGAGCTTCCGGCTTGGTGCCCAACGTGGTTGTGTTA	2285
Qy	2221	GTGGCAACGGTGCGAGCTCTGAAGATGCATGGAGGCGGGCCAAGTGTAACGGCTGGTGTT	2280

http://es/ScoreAccessWeb/GetItem.action?AppId=1057396...04_152742_us-10-573-969-1.rng&ItemType=4&startByte=0 (5 of 6)4/24/2008 1:13:55 PM

1561 CGGCTGGTTCCTTTAGTGAATGGTGTCAGAGAATTTTCAGAAATTCAGCTTGCTCGGCTA 1620

1626 CGGCTGGTTCCTTTAGTGAATGGTGTCAGAGAATTTTCAGAAATTCAGCTTGCTCGGCTA 1685

Db	2286	$\tt GTGGCAACGGTGCGAGCTCTGAAGATGCATGGAGGCGGGCCAAGTGTAACGGCTGGTGTT$	2345		
Qу	2281	CCTCTTAAGAAAGAATATACAGAGGAGAACATCCAGCTGGTGGCAGACGGCTGCTGTAAC	2340		
Db	2346	CCTCTTAAGAAAGAATATACAGAGGAGAACATCCAGCTGGTGGCAGACGGCTGCTGTAAC	2405		
Qy	2341	$\tt CTCCAGAAGCAAATTCAGATCACTCAGCTCTTTGGGGTTCCCGTTGTGGTGGCTCTGAAT$	2400		
Db	2406	CTCCAGAAGCAAATTCAGATCACTCAGCTCTTTGGGGTTCCCGTTGTGGTGGCTCTGAAT	2465		
Qy	2401	$\tt GTCTTCAAGACCGACACCCGCGCTGAGATTGACTTGGTGTGAGACTTGCAAAGCGGGCT$	2460		
Db	2466	GTCTTCAAGACCGACACCCGCGCTGAGATTGACTTGGTGTGTGAGACTTGCAAAGCGGGCT	2525		
Qy	2461	${\tt GGTGCCTTTGATGCAGTCCCCTGCTATCACTGGTCGGTTGGTGGAAAAGGATCGGTGGAC}$	2520		
Db	2526	GGTGCCTTTGATGCAGTCCCCTGCTATCACTGGTCGGTTGGTGGAAAAGGATCGGTGGAC	2585		
Qy	2521	$\tt TTGGCTCGGGCTGTGAGAGAGGCTGCGAGTAAAAGAAGCCGATTCCAGTTCCTGTATGAT$	2580		
Db	2586	TTGGCTCGGGCTGTGAGAGAGGCTGCGAGTAAAAGAAGCCGATTCCAGTTCCTGTATGAT	2645		
Qy	2581	$\tt GTTCAGGTTCCAATTGTGGACAAGATAAGGACCATTGCTCAGGCTGTCTATGGAGCCAAA$	2640		
Db	2646	GTTCAGGTTCCAATTGTGGACAAGATAAGGACCATTGCTCAGGCTGTCTATGGAGCCAAA	2705		
Qy	2641	${\tt GATATTGAACTCTCCTGAGGCACAAGCCAAAATAGATCGTTACACTCAACAGGGTTTT}$	2700		
Db	2706	GATATTGAACTCTCTCCTGAGGCACAAAATAGATCGTTACACTCAACAGGGTTTT	2765		
Qу	2701	GGAAATTTGCCCATCTGCATGGCAAAGACCCACCTTTCTCTATCTCACCAACCTGACAAA	2760		
Db	2766	GGAAATTTGCCCATCTGCATGGCAAAGACCCACCTTTCTCTATCTCACCAACCTGACAAA	2825		
Qу	2761	${\tt AAAGGTGTGCCAAGGGACTTCATCTTACCTATCAGTGACGTCCGGGCCAGCATAGGCGCT}$	2820		
Db	2826	AAAGGTGTGCCAAGGGACTTCATCTTACCTATCAGTGACGTCCGGGCCAGCATAGGCGCT	2885		
Qу	2821	${\tt GGGTTCATTTACCCTTTGGTCGGAACGATGAGCACCATGCCAGGACTGCCCACCCGGCCC}$	2880		
Db	2886	GGGTTCATTTACCCTTTGGTCGGAACGATGACCATGCCAGGACTGCCCACCCGGCCC	2945		
Qу	2881	TGCTTTTATGACATAGATCTTGATACCGAAACAGAACAAGTTAAAGGCTTGTTC 2934			
Db		TGCTTTTATGACATAGATCTTGATACCGAAACAGAACAAGTTAAAGGCTTGTTC 2999			
EndFragment					